it's 'zon

Amazon yet again expands its presence in Houston

A new Amazon delivery station is headed to League City. Photo courtesy of Amazon

Jeff Bezos' global powerhouse is showing no signs of slowing; indeed, its Houston-area footprint is growing. Amazon Logistics has announced plans to open a new 180,000-square-foot delivery station located in League City.

This new outpost promises to power Amazon's last-mile delivery capabilities to speed up deliveries for customers specifically in the Galveston County area, per a release.

Just what is an Amazon delivery station? Simply put, packages are shipped to delivery stations from neighboring Amazon fulfillment and sortation centers and loaded onto vehicles for final delivery to customers.

Amazon brass projects the site located at 2455 Tuscan Lakes Blvd. to open in early 2022. Along with obvious delivery improvement for area residents, the new center will offer plenty of local job opportunities. Candidates can earn an industry-leading minimum starting wage of $15 per hour; full-time employees receive comprehensive benefits, including full medical, vision, and dental insurance as well as a 401(k) with an impressive 50-percent company match.

(Those interested should visit https://www.amazondelivers.jobs/ for information on job postings and to apply online.)

Delivery stations also offer entrepreneurs the opportunity to build their own business delivering Amazon packages, as well as independent contractors the flexibility to be their own boss and create their own schedule delivering for Amazon Flex, the company notes.

As CultureMap previously reported, Amazon opened four Houston-area delivery stations in March.

"We are extremely excited about Amazon coming to League City," said League City mayor Pat Hallisey in a statement. "Not only will it bring jobs, but it will benefit a large majority of our residents, as well as those in neighboring cities, who regularly shop on Amazon."

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted